Orforglipron Matches Insulin Safety, Beats It on Blood Sugar Control

Researchers have demonstrated that the oral medication "orforglipron" achieves cardiovascular safety levels similar to those of insulin glargine in patients with type 2 diabetes. The findings also indicate a greater improvement in blood glucose control compared to the injectable standard.

The data were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) held in Milan, Italy, and published in the journal "The Lancet." The study was sponsored by Eli Lilly, the manufacturer of the drug.

Study Design and Participant Profile

The trial involved 2,749 individuals diagnosed with type 2 diabetes. Among these participants, 85.9% suffered from cardiovascular disease, and 37.5% had chronic kidney disease. Subjects were randomly assigned to two groups: one taking "orforglipron" once daily, and the other receiving daily injections of insulin glargine.

Investigators followed the participants for an average of two years to monitor major adverse cardiovascular events. These endpoints included death from cardiovascular causes, non-fatal heart attacks, non-fatal strokes, and hospitalization due to unstable angina.

Cardiovascular Outcomes Analysis

Major cardiovascular events occurred in 4.2% of the "orforglipron" group, compared to 5% of those receiving insulin glargine. The drug met the pre-specified statistical criterion to demonstrate non-inferiority regarding safety relative to insulin glargine. While the risk of such events was approximately 16% lower with "orforglipron," this difference did not reach statistical significance.

During the follow-up period, the study recorded 62 deaths. There were 19 deaths in the "orforglipron" arm and 43 in the insulin glargine arm. Researchers considered all but one of these fatalities unrelated to the treatment.

Superior Glycemic and Weight Control

In terms of glycemic management, "orforglipron" outperformed insulin glargine in reducing hemoglobin A1c (HbA1c), a marker reflecting average blood sugar levels. It also resulted in greater body weight reduction. By week 52, 65.7% of patients taking "orforglipron" achieved an HbA1c level below 7%, versus 46% in the insulin glargine group. Furthermore, 53.8% reached a level of 6.5% or lower, compared to 26.8% in the control group.

Weight loss metrics showed a distinct advantage for the oral drug. 63.1% of "orforglipron" users lost at least 5% of their body weight, compared to 13.4% of insulin glargine recipients. Additionally, 35.6% lost at least 10% of their weight versus 4.4% in the insulin group, while 15.1% lost at least 15% compared to just 1.3%.

Safety Profile and Side Effects

Gastrointestinal side effects were more frequent with "orforglipron," occurring in 62.1% of participants versus 14.2% of those treated with insulin glargine. These issues constituted the most common reason for discontinuing therapy. Conversely, severe or clinically significant hypoglycemia was less common with "orforglipron," recorded in 6.8% of participants compared to 19.2% in the insulin glargine group.